End Stage Renal Disease on DialysisNCT07014111
Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD
A study testing Fight Fatigue in people with End Stage Renal Disease on Dialysis, run by University of Illinois Chicago at 1 site in United States.
Trial summary
Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- End Stage Renal Disease on Dialysis
- What is being tested?
- Fight Fatigue
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Sep 2025to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of ESKD diagnosis and receiving hemodialysis for at least 3 months
- Can read and speak English
- Fatigue measured via visual analogue scale, score ≥4 over the last week
- Able to stand and walk one block
- Has a cell phone that can receive text messages
Who cannot join
- Patient's nephrologist refuses for them to participate
- Unstable angina
- Unstable pulmonary disease or pulmonary symptoms that preclude participation
- Lower-extremity amputation without prosthetic (BKA, AKA) -Orthopedic or neurologic condition that would preclude walking or tensing/releasing of muscles-
- Cognitive impairment that, in the judgement of the research team, precludes trial participation
- Participation in the formative phase of the development of Fight Fatigue
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UI Health/University of Illinois Chicago
Chicago, Illinois, 60612
Mary Hannan, 312-355-4838, mhanna22@uic.edu
About this study
Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis.
- Conditions
- End Stage Renal Disease on Dialysis
- Being tested
- Fight Fatigue, Attention Control
- Keywords
- Fatigue
- Medical subject headings
- Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fight FatigueBehavioural
Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.
Attention ControlOther
End-stage kidney disease education
| Study group | Role | What they receive |
|---|---|---|
| Fight Fatigue | Experimental | Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages Receives: Behavioral: Fight Fatigue |
| Attention Control | Active comparator | End-stage kidney disease education, followed by text messages (over 12 weeks) Receives: Other: Attention Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of recruitment
Recruitment metrics (enrolled/invited)
Measured: Baseline to week 12
Feasibility of retention
Retention in the study from baseline to week 12
Measured: Baseline to week 12
Acceptability
Participant rating of acceptability (e.g., enjoyable, easy to understand) via Likert scale questions and open ended questions
Measured: End of study (Week 12)
Adherence to the study protocol
Adherence to the intervention measured with adherence to step counts, number/duration of accesses on the study-specific website, and adherence to study procedures as evaluated with number of text messages read/sent messages read.
Measured: Baseline to week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2025
- Study start2 Sep 2025
- Primary completionFeb 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for End Stage Renal Disease on DialysisStudies of the same condition, open and under way.
- More trials run by University of Illinois ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Illinois Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH)
- Responsible party
- Principal investigator, Mary Hannan, University of Illinois Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07014111
- Sponsor's protocol ID
- STUDY2025-0281
- Other IDs
- R34AT012770
- Status last verified
- Aug 2026
- First submitted
- 23 May 2025
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Hannan MF, Fischer MJ, deMartelly V, Lif N, Tintle N, Doorenbos AZ. A combined progressive muscle relaxation and walking intervention for adults with end-stage kidney disease receiving hemodialysis (Fight Fatigue): Study development and protocol. Contemp Clin Trials Commun. 2026 Mar 24;51:101631. doi: 10.1016/j.conctc.2026.101631. eCollection 2026 Jun.
PubMed 41952779
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD
- ClinicalTrials.gov ID
- NCT07014111
- Acronym / sponsor ID
- STUDY2025-0281
- Conditions
- End Stage Renal Disease on Dialysis
- Keywords
- Fatigue
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of Illinois ChicagoUniversity, hospital or other
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH)
- Study start
- 2 Sep 2025 (actual)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 10 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fight Fatigue | Experimental | Behavioral: Fight FatigueCombined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages |
| Attention Control | Active comparator | Other: Attention ControlEnd-stage kidney disease education, followed by text messages (over 12 weeks) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of ESKD diagnosis and receiving hemodialysis for at least 3 months
- Can read and speak English
- Fatigue measured via visual analogue scale, score ≥4 over the last week
- Able to stand and walk one block
- Has a cell phone that can receive text messages
Key exclusion criteria (6 listed)
- Patient's nephrologist refuses for them to participate
- Unstable angina
- Unstable pulmonary disease or pulmonary symptoms that preclude participation
- Lower-extremity amputation without prosthetic (BKA, AKA) -Orthopedic or neurologic condition that would preclude walking or tensing/releasing of muscles-
- Cognitive impairment that, in the judgement of the research team, precludes trial participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fight FatigueCombined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages. | Behavioural | Fight Fatigue |
| Attention ControlEnd-stage kidney disease education | Other | Attention Control |
Primary outcome
Feasibility of recruitment
Time frame: Baseline to week 12
Recruitment metrics (enrolled/invited)
Feasibility of retention
Time frame: Baseline to week 12
Retention in the study from baseline to week 12
Acceptability
Time frame: End of study (Week 12)
Participant rating of acceptability (e.g., enjoyable, easy to understand) via Likert scale questions and open ended questions
Adherence to the study protocol
Time frame: Baseline to week 12
Adherence to the intervention measured with adherence to step counts, number/duration of accesses on the study-specific website, and adherence to study procedures as evaluated with number of text messages read/sent messages read.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Derived from this study: PubMed 41952779Hannan MF, Fischer MJ, deMartelly V, Lif N, Tintle N, Doorenbos AZ. A combined progressive muscle relaxation and walking intervention for adults with end-stage kidney disease receiving hemodialysis (Fight Fatigue): Study development and protocol. Contemp Clin Trials Commun. 2026 Mar 24;51:101631. doi: 10.1016/j.conctc.2026.101631. eCollection 2026 Jun.
Related trials for End Stage Renal Disease on Dialysis
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Not yet recruitingPhase 1/2
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
End Stage Renal Disease, Fatigue
Not yet recruiting
Effects of Horticultural Therapy on Acute Stress and Salivary Cortisol Levels in Hemodialysis Patients
End-Stage Renal Disease, Renal Dialysis
RecruitingPhase 4
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
RecruitingPhase 2
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fight Fatigue in people with End Stage Renal Disease on Dialysis, run by University of Illinois Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mary Hannan, PhD (3123554838, mhanna22@uic.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of recruitment (time frame: Baseline to week 12). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07014111, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.